Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer

The prognosis of patients with unresectable or recurrent pancreatic cancers is very poor. Prior to development of nab-paclitaxel (PTX) plus gemcitabine (GEM) therapy and FOLFIRINOX therapy, there was no recommended third-line chemotherapy after 5-fluorouracil (5-FU) and GEM-based regimens. The prese...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Mol Clin Oncol
Egile Nagusiak: Tajima, Hidehiro, Okazaki, Mitsuyoshi, Yamaguchi, Takahisa, Ohbatake, Yoshinao, Okamoto, Koichi, Nakanuma, Shinichi, Terai, Shiro, Sakai, Seisho, Kinoshita, Jun, Makino, Isamu, Nakamura, Keishi, Hayashi, Hironori, Oyama, Katsunobu, Inokuchi, Masafumi, Miyashita, Tomoharu, Takamura, Hiroyuki, Ninomiya, Itasu, Fushida, Sachio, Ohta, Tetsuo
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2018
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844031/
https://ncbi.nlm.nih.gov/pubmed/29556385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1579
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak